Close Menu

NEW YORK – Blood culture collection firm Kurin said on Tuesday that the US Food and Drug Administration has cleared the firm's novel push-button needle.

"Development of our proprietary needle provides us vertical integration and also allows us to offer superior options to our customers," Kurin CEO Bob Rogers said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.